Regular Research Article

Diagnostic Instability Over Time in the Late-Onset Frontal Lobe Syndrome: When Can We Say it's FTD?

Sterre C.M. de Boer, M.D., Flora Gossink, M.D., Ph.D.,
Welmoed Krudop, M.D., Ph.D., Everard Vijverberg, M.D., Ph.D.,
Sigfried Schouws, Ph.D., Lianne Maria Reus, Ph.D.,
Yolande A.L. Pijnenburg, M.D., Ph.D., Annemiek Dols, M.D., Ph.D.

ARTICLE INFO

ABSTRACT

Objectives: Distinguishing sporadic behavioral variant of frontotemporal dementia (bvFTD) from late-onset primary psychiatric disorders (PPD) remains challenging with the lack of robust biomarkers. An early bvFTD misdiagnosis in PPD cases and vice-versa is common. Little is known about diagnostic (in)stability over longer period of time. We investigated diagnostic instability in a neuropsychiatric cohort up to 8 years after baseline visit and identified which clinical hallmarks contribute to diagnostic instability. Design: Diagnoses of participants of the late-onset frontal lobe (LOF) study were collected from the baseline visit (T0) and the 2-year follow-up visit (T2). Clinical outcomes were retrieved 5−8 years after baseline visit (T_{final}). Endpoint diagnoses were categorized into bvFTD, PPD and other neurological disorders (OND). We calculated the total amount of participants that switched diagnosis between T0-T2 and T2-T_{final}. Clinical records of participants that switched diagnosis were assessed. Results: Of the 137 patients that were included in the study, the final diagnoses at T_{final} were bvFTD 24.1% (n = 33), PPD 39.4% (n = 54), OND 33.6% (n = 46) and unknown 2.9% (n = 4). Between T0 and T2, a total of 29 (21.2%) patients switched diagnosis. Between T2 and T_{final}, 8 (5.8%) patients switched diagnosis.

From the Alzheimer Center Amsterdam, Neurology (SCDB, WK, EV, LMR, YALP), Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, The Netherlands; Amsterdam Neuroscience (SCDB, WK, EV, LMR, YALP), Neurodegeneration, Amsterdam, The Netherlands; Reinier van Arkel, Geriatric and Hospital Psychiatric Centre (COZ) (FG), Jeroen Bosch Hospital, Den Bosch, The Netherlands; Department of Psychology and Psychiatry, Antonius Ziekenhuis Utrecht (WK), Utrecht, The Netherlands; Department of Old Age Psychiatry (SS), GGZ inGeest Specialized Mental Health Care, Amsterdam, The Netherlands; Amsterdam UMC, Vrije Universiteit Amsterdam, Psychiatry (SS), Amsterdam Public Health research institute, Amsterdam, The Netherlands; Center for Neurobehavioral Genetics (LMR), University of California, Los Angeles, Los Angeles, CA; and the Department of Psychiatry (AD), UMC Utrecht Brain Center, University Utrecht, Utrecht, The Netherlands. Send correspondence and reprint requests to Sterre de Boer M.D., Alzheimer Center Amsterdam, De Boelelaan 1118, 1081 HZ Amsterdam. e-mail: scm.deboer@amsterdamumc.nl

Prolonged follow-up identified few cases with diagnostic instability. Major contributors to diagnostic instability where a nonconverting diagnosis of possible bvFTD and a probable bvFTD diagnosis based on informant-based history and an abnormal FDG-PET scan whilst having a normal MRI. **Conclusion:** *Considering these lessons, a FTD diagnosis remains stable enough to conclude that 2 years is sufficient to say if a patient with late-life behavioral disorder has FTD.* (Am J Geriatr Psychiatry 2023; 31:679−690)

Highlights

- **What is the primary question addressed by this study?**
  We investigated diagnostic instability over time of patients with a late-onset behavioural disorder included in a neuropsychiatric cohort and identified clinical hallmarks that contribute to diagnostic instability.
- **What is the main finding of this study?**
  Between baseline and the 2 year follow-up visit 21.2% of all patients diagnosed with frontotemporal dementia, primary psychiatric disorders or other neurological disorders switched diagnosis. After the 2-year follow-up only 5.8% of all patients switched diagnosis. Clinical characteristics contribute to diagnostic instability were identified.
- **What is the meaning of the finding?**
  A bvFTD diagnosis remains stable enough to say a patient with late-life behavioral disorder has bvFTD if our clinical lessons are taken into consideration.

INTRODUCTION

The behavioral variant of frontotemporal dementia (bvFTD) is the most prevalent form of FTD and is associated with progressive degeneration of the frontal lobes, anterior temporal lobes, or both.[1,2] Neuropsychiatric symptoms overshadow the cognitive disabilities, especially in the early disease phase[3−6] and at an earlier age of onset.[7] Alterations in social cognition often represent the earliest and core symptoms of bvFTD, resulting in emotional disengagement and socially inappropriate responses or activities.[8−10] Apathy, inertia, disinhibition, loss of empathy or stereotyped, compulsive behaviors are common clinical features in bvFTD. Consequently, due to this heterogeneous and often predominantly behavioral clinical presentation, both other neurodegenerative diseases as well as various psychiatric disorders are crucial to consider as a differential diagnosis.[6]

A bvFTD diagnosis is made following the clinical consensus criteria developed by an international expert group.[4] A *possible* bvFTD is a merely syndromic, mainly behavioral, diagnosis, while a *probable* bvFTD is supported by imaging findings. A *definite* bvFTD diagnosis is made if pathological confirmed or if a causal FTD mutation is present, the latter also known as genetic FTD. The deficits and behavioral disturbances should not be accounted for by non-neurodegenerative diseases and/or a psychiatric diagnosis in order to accurately diagnose bvFTD.

However, discerning non-genetic, or sporadic, bvFTD from a heterogeneous neuropsychiatric population remains challenging, particularly since robust biomarkers for sporadic bvFTD and PPD are lacking. This challenge is illustrated by the high percentages reported, ranging from 50% to 71%, of initial psychiatric diagnoses in bvFTD[11−13] and a delay of 6 years to diagnose bvFTD.[14] We have previously shown that a bvFTD diagnosis is unstable within a follow-up period of 2 years in the late onset frontal lobe (LOF) study, with 49% of bvFTD patients switching diagnosis.[15] This instability has major impact on patients and their family as misdiagnosis of PPD in bvFTD and vice versa in receiving treatment and correct information of the disease and prognosis.

As a response to this diagnostic challenge, the Neuropsychiatric International Consortium of Frontotemporal

Dementia (NIC-FTD) has established clinical recommendations to distinguish bvFTD from PPD.[16] These recommendations include clinical and neuroimaging follow-up in diagnostic ambiguous cases. The duration of this follow-up in order to achieve diagnostic precision remains elusive and little is known about the diagnostic (in)stability after 2 years of follow-up in a neuropsychiatric cohort.

The aim of the present study was to investigate diagnostic instability of patients with a late-onset behavioral disorder from the LOF study. Second, we aimed to identify clinical hallmarks that contribute to diagnostic instability.

METHODS

Patients

Subjects included participants of the LOF study. The LOF study is an observational study that included subjects with behavioral changes with onset between the ages of 45 and 75 years. Participants were recruited and followed-up in the memory clinic of the Alzheimer Centre Amsterdam and the outpatient clinic of psychiatry of the GGZ inGeest, Amsterdam, The Netherlands, between 2011 and 2015. Demographics and examination variables, including a neuropsychological examination, imaging and genetic screening were collected at baseline (T0). Following standard diagnostic work-up, cerebrospinal fluid (CSF) was collected at the memory clinic for n = 107 subjects before enrolment in the LOF-study to screen for the presence of AD-biomarkers.[17] Two years after baseline (T2), the LOF-study participants were invited to return to the outpatient clinic for a re-assessment, similar to the baseline visit. The LOF-study followed clinical criteria of the National Institute on Aging-Alzheimer's Association guidelines for Alzheimer disease, the International Consensus Diagnostic Criteria for dementia with Lewy bodies, the Diagnostic and Statistical Manual of Mental Disorders IV for psychiatric disorders, the National Institute of Neurological Disorders and Stroke and Association Internationale pour la Recherché et I'Enseignement en Neurosciences (NINDS-AIREN) criteria for vascular dementia and the International bvFTD Criteria Consortium for bvFTD.[4,18−20] With adherence to DSM-IV, 'relational problems' in this study were defined as "a pattern of interaction between spouses or partners characterized by negative communication (e.g., criticisms), distorted communication (e.g., unrealistic expectations), or noncommunication (e.g., withdrawal) that is associated with clinically

FIGURE 1. Flowchart of the LOF-study visits, clinical follow-up and retrospective diagnosis retrieval. Dark grey: LOF-study. Light gray: retrieval clinical outcome current study. Abbreviations: LOF-study: Late-Onset Frontal lobe study. T2: study follow-up LOF study 2 years after baseline visit. T_final: clinical outcome 5-8 years after baseline visit of the LOF-study.

significant impairment". A total of n = 112 (81.7%) participants completed the T2 visit in the clinic.

Specific inclusion and exclusion criteria, clinical assessment, imaging protocol, diagnostic procedure at baseline and informed consent procedure have been described previously.[21]

Diagnoses T_{final}

Five to 8 years after baseline visit (T_{final}), the final diagnosis of the patient was retrieved. Of the initial 137 LOF-study participants, n = 52 (38.0%) subjects still received clinical follow-up at the memory clinic of the Alzheimercentrum Amsterdam. For the remaining n = 85 cases, the clinical outcome was retrieved by either contacting their general practitioner, their psychiatrist/neurologist/geriatrist or other medical specialist. The general practitioner in the Netherlands receives written correspondence on all patient's visits to medical specialists for diagnostics, therapies and/or hospital admissions. Patients were lost to follow up when they refused follow-up or when the patient died while diagnosis remained uncertain or unknown. With this T_{final} method we were able to collect information LOF-study participants that were not seen at the 2-year follow-up visit of the LOF-study but did have information available around the anticipated 2-year follow-up visit that was adequate to come to a diagnosis. This led to retrieving diagnoses for n = 9 cases at the time of the T2 visit (Fig. 1). The (retrieved) diagnoses were grouped into 'bvFTD', 'PPD' and 'other neurological disorders (OND)'.

Clinical Measurements

At baseline of the LOF-study, demographic variables and clinical measurements including mini-mental state exam (MMSE), montgomery asberg depression rating scale (MADRS), frontal assessment battery (FAB), frontal behavioral inventory (FBI) and stereotypy rating inventory (SRI), neuropsychological executive dysfunction determined by translating z-scores to a dichotomous variable and the Ekman faces test were determined for all participants as previously described.[21,22] The presence of typical FTD like atrophy patterns in MRI and frontotemporal (FT) hypometabolism in FDG-PET were assessed by visual inspection by a trained neurologist as described in the study of Vijverberg et al.[23] The baseline measurements were compared between the endpoint (T_{final}) diagnostic groups.

Genetic Testing in LOF Study

All participants, regardless of baseline diagnosis or family history, were screened for the length of the repeat expansion in the chromosome 9 open reading frame 72 (*C9orf72*) since bvFTD caused by a *C9orf72* repeat expansion can often debut with psychiatric symptoms[24] such as late-onset psychosis and/or bipolar disorder.[25] Participants with a positive family history for dementia were also screened for the presence of a mutation in the microtubule associated protein tau (*MAPT*) and progranulin (*GRN*).

Statistics

IBM SPSS Statistics for Windows was used to perform statistical analyses, version 24. The baseline characteristics were compared between the final three diagnostic groups. Normally distributed continuous values were compared between diagnostic groups using an one way ANOVA, and Bonferonni as post-hoc test. Continuous values without a normal distribution were examined using a Kruskall-Wallis and post-hoc Mann-Whitney U tests. Results were considered to be statistically significant if $p < 0.05$, except for the results from the Mann-Whitney U test being performed after the Kruskal-Wallis test ($p < 0.05$ / three diagnostic groups, $p < 0.017$). Pearson's χ^2-test was used when dichotomous variables were compared. For between-group comparisons with ≤ 5 observations, a Fisher's exact test was performed. Figure 2 was made using R studio version 4.0.3, using the "networkD3" package.[26]

Ethical Considerations

The study was approved by the Medical Ethical Committee of the AmsterdamUMC, location VUmc, Amsterdam.

Results

Five to 8 years after baseline visit, the final diagnoses were the following for the 137 patients; bvFTD 24.1% (n = 33), PPD 39.4% (n = 54), OND 33.6%

TABLE 1. Diagnoses at Baseline and Final Diagnosis (T_final)

		Baseline (T0)		T_final	
	n	**%**		**n**	**%**
Frontotemporal Dementia Total	**55**	**40.2**		**33**	**24.1**
Possible bvFTD	10	7.3		0	0
Probable bvFTD	45	32.8		29	21.2
FTD-ALS				5	
Definite bvFTD				4	2.9
Tauopathy				1	
C9orf72 expansion				2	
GRN-mutation				1	
Primary Psychiatric Disorders Total	**51**	**37.2**		**54**	**39.4**
Schizophrenia	2	1.5		1	0.7
Major depression	20	14.6		12	8.8
Minor depression	5	3.6		2	1.5
Obsessive Compulsive Disorder	2	1.5		0	0.0
Bipolar Disorder	6	4.4		6	4.4
Autism Spectrum Disorder	3	2.2		3	2.2
Personality disorder	2	1.5		5	3.6
Other psychiatric disorder problems	4	2.9		13	9.5
Relational problems	3	2.2		5	3.6
Subjective cognitive decline	4	2.9		5	3.6
Other Psychiatry	0			2	1.5
Other Neurological Disorders Total	**31**	**22.6**		**46**	**33.6**
Alzheimer's disease	7	5.1		9	6.6
Lewy Body Dementia	3	2.2		4	2.9
Vascular Dementia	2	1.5		7	5.1
Vascular MCI	4	2.9		3	2.2
Other Dementia	7	5.1		12	8.8
Other Neurology	8	5.8		11	8.0
Unknown	*0*			4	2.9
Total	*137*			*137*	

Notes: bvFTD: behavioral variant Frontotemporal Dementia; C9orf72 expansion: Chromosome 9 open reading frame 72 repeat expansion; FTD-ALS: frontotemporal dementia-amyotrophic lateral sclerosis; GRN progranulin.

(n = 46) and unknown 2.9% (n = 4) (see Table 1). Most bvFTD patients were sporadic, with only three bvFTD patients (2.2%) carrying a genetic mutation *(C9orf72* n = 2, *GRN* mutation n = 1).

switched to the PPD group. Sixteen patients were lost to follow up at T2. Resulting in a total of 29 patients in the bvFTD group, 54 in the PPD group and 38 patients in the OND group at T2.

Diagnostic Instability T0−T2

Between the baseline and T2 visit, a total of 29 (21.2%) patients switched diagnoses. Twelve patients from the bvFTD group switched to the PPD group, of which six patients were initially diagnosed with possible bvFTD and six with probable bvFTD. Six patients switched from a bvFTD to an OND diagnosis. Of the baseline PPD group, one patient switched to bvFTD and seven patients switched to the OND group. Of the baseline OND group, three patients

Diagnostic Instability T2−T_final

Between T2 and T_final, a total of eight (5.8%) patients switched diagnosis. In the bvFTD group, two patients switched to PPD and two switched to OND. In the PPD group, two patients switched to bvFTD and two patients switched to OND. From the OND group, no patients switched diagnosis after T2 (Fig. 2). The clinical characteristics of the patients that switched between T0 and T2 and between T2 and T_final are shown in Table 3.

FIGURE 2. Patients that switched diagnosis between T0 and T2 and T2 and T_{final}. T0: bvFTD n = 55, PPD n = 51, OND n = 31 and unknown n = 0. T2: bvFTD n = 29, PPD n = 54, OND n = 38 and unknown n = 16. Tfinal: bvFTD n = 33, PPD n = 54, OND n = 46 and unknown n = 4. Abbreviations: FTD: frontotemporal dementia; PPD: primary psychiatric disorders; OND: other neurological disorders. T0 = baseline visit, T2 = follow-up visit 2 years after baseline, T_{final} = 5−8 years after baseline visit.


TABLE 2. Baseline clinical and demographical characteristics per diagnostic group at final diagnosis (T_{final}).

	bvFTD (n=33)	PPD (n=54)	OND (n=46)	p-value
Age at presentation (years), mean (SD)	63.3 (6.8)	59.6 (6.5)	64.4 (6.6)	0.001[a]
Male gender, n (%)	19 (57.6)	44 (81.1)	33 (71.7)	0.054[b]
Education (years) median (IQR)	10.5 (4)	10.0 (4)	12.0 (5)	0.159[c]
Disease duration (years) median (IQR)	3.5 (7)	3.0 (2)	3.0 (3)	0.659[c]
Positive psychiatric history, n (%)	8 (24.0) *	28 (51.9) *, ±	13 (28.3) ±	0.011[b]
FBI, mean (SD)	25.1 (9.3)	25.0 (9.1)	23.3 (10.0)	0.613[a]
SRI, median (IQR)	9.5 (18) *, ₤	4.0 (8)*	1.5 (8)₤	<0.001[c]
MADRS, median (IQR)	6.5 (11) *	12.5 (19)*,±	6.5 (8)±	<0.003[c]
MMSE, median (IQR)	27.0 (5)	27.0 (2)	26.5 (4)	0.512[c]
FAB, median (IQR)	15.0 (4)	16.0 (5)	15.5 (3)	0.052[c]
Ekman Faces Test, mean (SD)	30.8 (9.8)*,₤	40.2 (7.5) *	37.5 (8.2)₤	<0.001[a]
Executive dysfunction, n (%)	6 (18.2)	8 (14.8)	7 (15.2)	0.908[b]
FTD like atrophy on MRI, n (%)	21 (63.6)*, ₤	2 (3.7) *	4 (8.7) ₤	<0.001[b]
FT hypometabolism on FDG-PET, n (%) [missing]	15 (93.8) *, ₤	13 (30.2) *	7 (22.6) ₤	<0.001[b]

Abbreviations: SD = standard deviation, IQR = interquartile range, bvFTD: behavioural variant frontotemporal dementia; CSF = Cerebrospinal Fluid; FAB = Frontal Assessment Battery; FBI = Frontal Behavioral Inventory; FDG-PET = [¹⁸F]-fluorodeoxyglucose-positron emission tomography; FT = frontotemporal; MADRS = Montgomery Asberg Depression Rating Scale; OND: other neurologic disease; PPD: primary psychiatric disorder; SRI = Stereotypy Rating Inventory.

Group differences: age at presentation (years): (ANOVA, $F_{(2, 132)}$ = 7.03, p = 0.001), male gender %: ($\chi 2$ (1, N = 133) = 5.84, p = 0.054), Education in years: (H(2) = 3.70, p = 0.159), Disease Duration: (H(2) = 0.83, p = 0.659), Positive psychiatric history: ($\chi 2$ (1, N = 133) = 8.94, p = 0.011), FBI: (ANOVA, $F_{(2, 130)}$ = 0.49, p = 0.613), SRI: (H(2) = 17.36 p<0.001), MADRS: (H(2) = 11.45 p = 0.003), MMSE: (H(2) = 1.34, p = 0.512), FAB: (H(2) = 5.91 p = 0.052), Ekman Faces (ANOVA, $F_{(2, 103)}$ = 9.97, p<0.001), Executive dysfunction: ($\chi 2$ (1, N = 133) = 0.19, p = 0.908), FTD like atrophy on MRI: ($\chi 2$ (1, N = 133) = 51.33, p<0.001), FT hypometabolism on FDG-PET: ($\chi 2$ (1, N = 87) = 37.83, p<0.001).

Results with * differ significantly between the bvFTD and PPD group. Results with ± differ significantly between the PPD and OND group. Results with ₤ differ significant between the bvFTD and OND group.

[a] One way ANOVA.
[b] Pearson χ square analysis.
[c] Kruskall Wallis test.

TABLE 3. Clinical Characteristics of Patients Switching Diagnoses Between T0 and T2 and T2 and T_{final}

	T0−T2		T2−T_{final}	
	Switch	**No Switch**	**Switch**	**No Switch**
n (% total cohort)	29 (21.2)	92 (67.2)[n=16 missing]	8 (5.7%)	125 (91.2)[n=4 missing]
% male	79.3	69.6	75.0	72.0
Mean age at presentation (SD)	63.7 (6.4)	61.4 (6.8)	65.9 (4.6)	61.9 (7.0)
% MRI T2 made	75	70	75	63
MRI FTD like atrophy T0, +/-	3/26	22/70	1/7	26/99
FDG-PET FTD like pattern T0, +/-	11/14	19/40	1/7	34/48

Notes: FTD: frontotemporal dementia; FDG-PET: [18F]-fluorodeoxyglucose-positron emission tomography; MRI: magnetic resonance imaging; SD: standard deviation.

Baseline Clinical and Demographical Characteristics

The baseline demographics and clinical examination of the patients in each final diagnosis group (T_{final}) are shown in Table 2. The age at presentation (ANOVA, $F_{(2, 132)} = 7.03$, $p < 0.01$), prevalence of positive psychiatric history (χ^2 (1, N = 133) = 8.94, $p = 0.01$), the SRI score (H(2) = 17.36 $p < 0.001$), MADRS score (H(2) =11.45 $p < 0.01$), Ekman Faces test score (ANOVA, $F_{(2, 103)} = 9.97$, $p < 0.001$), the presence of FTD-like atrophy on the MRI scan (χ^2 (1, N = 133) = 51.33, $p < 0.001$) and the presence of FT hypometabolism on the FDG-PET scan (χ^2 (1, N = 87) = 37.83, $p < 0.001$) differed significantly between the bvFTD, PPD, and OND group. Post-hoc comparison showed that the PPD were significantly younger than bvFTD (mean Δ 3.7 years, SD = 1.46, $p = 0.04$) and OND (mean Δ 4.8 years, SD = 1.33, $p < 0.01$). There was no significant difference in age at presentation between bvFTD and OND (mean Δ 1.1 years, SD = 1.51, $p = 1.00$). There was a higher prevalence of positive psychiatric history in the PPD group (51.9%) compared to the bvFTD group (24,0%, χ^2 (1, N = 87) = 6.4, $p = 0.01$) and compared to the OND group (28.3%, χ^2(1, N = 100) = 5.72, $p = 0.02$).

The SRI score was higher in the bvFTD group (median 9.5) compared to the PPD group (median 4.0, z = -3,15, $p < 0.01$) and to the OND group (median 1.5, z = -4.00, $p < 0.01$). There was no significant difference in SRI score between the PPD and OND group (z = -1,37, $p = 0.17$). The PPD group had a higher MADRS score (median 12.5) compared to the bvFTD group (median 6.5, z = -3.06 $p < 0.01$) and to the OND group (median 6.5, z = -2.55, $p = 0.01$). There was no difference in MADRS score between the bvFTD and OND group (z = -0.83, $p = 0.41$). Bonferroni post-hoc comparison showed that the bvFTD group has a lower score on the Ekman Faces test compared to the PPD group (mean Δ 9.35 points, SD = 2.10, $p < 0.001$) and to the OND group (mean Δ 6.70 points, SD = 2.16, $p < 0.01$). No significant differences were found in the Ekman Faces test between the PPD and OND group (mean Δ 2.73 points, SD = 1.88, $p = 0.45$).

Comparing the presence of FTD like atrophy on the MRI scan between each groups showed a higher prevalence of FTD like atrophy in the bvFTD group (63.6%) compared to the PPD group (3.7%, Fisher's exact test, N = 87), $p < 0.001$) and compared to the OND group (8.7%, Fisher's exact test, N = 79, $p < 0.001$). This significant difference in presence of FTD-like atrophy on the MRI scan was not seen between PPD and OND (Fisher's exact test, N = 100, $p = 0.41$). Likewise, the bvFTD group showed a higher prevalence of FT hypometabolism (93.8%) compared to the PPD group (30.2%, Fisher's exact test, N = 59, $p < 0.001$) and to the OND group (22.6%, Fisher's exact test, N = 47 $p < 0.001$). This difference was not seen between the PPD and OND group (χ^2, (1, N = 74) = 0.54, $p = 0.47$).

No significant group differences between the three groups bvFTD, PPD and OND were found for sex (χ^2 (1, N=133) = 5.84, $p = 0.05$), education level (H (2) = 3.70, $p = 0.16$), disease duration (H(2) = 0.83, $p = 0.66$), FBI (ANOVA, $F_{(2, 130)} = 0.49$, $p = 0.61$), MMSE (H(2) = 1.34, $p = 0.51$), FAB (H(2) = 5.91 $p = 0.05$) and presence of executive dysfunction at neuropsychological examination (χ^2 (1, N = 133) = 0.19, $p = 0.91$).

FIGURE 3. Case vignettes of patients that switched diagnosis between T0 and T2.

i. *Six patients switched from possible bvFTD to PPD.*
After two years, three of these patients had relational problems, two patients had a mood disorder and one patient had an unclear psychiatric picture. None of these six patients had supporting imaging results. Results of Ekman faces test were below a cut off score of 46 for all six patients. The case with an unclear psychiatric picture scored low on the Ekman Faces test (<20) and on executive tasks in the neuropsychological test at baseline which, in combination with the clinical impression, led to the initial diagnosis of possible bvFTD. In the patients with the relational problems, a combination of mood symptoms, relationship problems and subjective memory complaints were present. In these patients, the informant-based history strongly pointed towards a bvFTD diagnosis at baseline whilst diagnostic clinical-rated instruments did not. The neuropsychological profile at baseline of the mood disorder patients were not supportive for a bvFTD diagnosis. One of the patients diagnosed with a mood disorder at T2, in parallel to the diagnostic work-up and follow-up, also consulted a psychiatrist and received non-pharmacological psychiatric treatment to help cope with life changing events that occurred in the years prior to the baseline visit. During the treatment, the patient's mood improved and at clinical follow-up, neuropsychological testing scores improved and the MRI remained normal. In hindsight, at baseline, the patient suffered from a depression with apathy which was completely in remission at T2. The other patient diagnosed with a mood disorder had, with the exception of two lacunar ischemic lesions, a normal MRI and normal neuropsychological test scores at T2. Moreover, a third informant present at T2 provided information that was not fitting for a possible bvFTD diagnosis. The patient still had an unclear clinical presentation and was finally labelled as a depression with agitation.

ii. *Six patients switched from probable bvFTD to PPD.*
Four patients were diagnosed with a mood disorder and two with relational problems. All six patients had a FDG-PET result supportive of bvFTD, only one patient also had an abnormal MRI. At baseline, in four out of these six 'converting' patients the neurologist and psychiatrist were convinced of a probable bvFTD diagnosis on the basis of a combination of 'clinical impression', a supportive informant based history and FDG-PET results supportive for a bvFTD diagnosis. The only patient having both an abnormal MRI and FDG-PET, was diagnosed with relational problems. The bvFTD diagnosis was mainly based at an informant based history in combination with mild bifrontal brain atrophy. In all six patients the score at the Ekman Faces test was below a cut of score of 46. In three patients, there was the relatively high score of the SRI (>10). Remarkably, none of these six patients had a neuropsychological profile supportive for a bvFTD diagnosis, despite mild executive problems in two patients. In retrospect, this combination of a non-supportive neuropsychological test with only mild atrophy warrants clinicians to be cautious giving a diagnosis of probable bvFTD.

iii. *One patient switched from PPD to possible bvFTD*
At baseline this patient was diagnosed with a major depression with psychotic features even though she fulfilled the clinical criteria of possible bvFTD. After two years of follow up the behavioral problems (mainly apathy) turned out to be progressive which led to a diagnosis of possible bvFTD. This patient switched back to a PPD diagnosis after two years (see patient B, Figure 4)

iv. *Six patients switched from probable bvFTD to OND.*
Three patients were diagnosed with other FTD spectrum diseases; two patients with semantic dementia (SD) and one with cortical basal syndrome (CBS). During follow-up the behavioral problems were less pronounced than the semantic deficits in the SD patients. Likewise, in CBS patients the behavioral disorders were less pronounced than the bradykinesia and apraxia. The other three patient fulfilled the Rascovsky criteria for bvFTD, but all three required additional examination to rule out the second differential diagnosis that was given: one patient switched diagnosis to multiple sclerosis (MS) after an additional MS-protocol MRI scan gave confirmation of MS-like lesions at the baseline MRI scan. One patient switched to Parkinson's disease dementia after confirmation of a DAT-SPECT scan. One patient switched to the diagnosis of post-anoxic encephalopathy after a non-progressive second MRI and an observation at the psychiatric ward during follow-up was not suspect for bvFTD.

v. *Seven patients switched from PPD to OND.*
Four patients switched from major depression disorder to other neurological disorders. One of these patients suffered from depression but over time autonomic dysfunction and movement disorder became more pronounced and the diagnosis switched to Multiple System Atrophy. Two of these patients switched to other dementia types (vascular dementia and progressive supranuclear palsy). The fourth major depression patient at baseline suffered from a depression that was almost completely in remission before he got a cardiac arrest close to the T2 visit after which he developed a cognitive disorder that was believed to be caused by a post-anoxic encephalopathy. One patient switched from a diagnosis of autism spectrum disorder to DLB. At baseline, this patient already showed symptoms of DLB such as REM sleep behavior disorder and mild rigidity but did not fulfill DLB criteria until his follow-up visit. One patient suffered from post-traumatic stress disorder and late onset behavioural changes that were caused by recent life changing events. The MRI at baseline showed mild vascular damage but this was not believed to be causally related to the presented symptoms. At follow-up, this patient developed progressive cognitive impairment and the MRI showed progression of the vascular lesions, causing the neurologist to switch diagnosis to vascular dementia. Likewise, the seventh patient changed diagnosis from subjective cognitive decline, possibly caused by mild mood problems, to vascular dementia after objectifying progression of memory symptoms and vascular lesions on the MRI scan.

vi. *Three patients switched from OND to PPD.*
One patient was diagnosed with vascular mild cognitive impairment (VCI) due to a small thalamic ischemic lesion at baseline but changed diagnosis to an unclear psychiatric mood disorder and subjective cognitive complaints that did not correlate with the ischemic lesion. One patient with auditory hallucinations and atypical behavioural symptoms was diagnosed with dementia with Lewy body (DLB) at baseline but switched diagnosis due to a non-supportive DAT-SPECT scan at follow-up. The patient was re-evaluated by a psychiatrist and neurologist and was diagnosed with bipolar disorder. The third patient was suffering from cognitive impairment, anxiety and behavioural change and was diagnosed with dementia due to obstructive sleep apnea syndrome (OSAS). The OSAS was successfully treated during follow-up. However, the symptoms did not improve and at the follow-up visit he was diagnosed with an anxiety disorder.

FIGURE 4. Case vignettes of patients that switched diagnosis between T2 and T$_{final}$.

One patient changed diagnosis from probable bvFTD (T2) to relational problems (T$_{final}$).
A. Patient A was a 58-year old male at first presentation at the neurologist. His wife reported clear behavioral changes including disinhibition and stereotypical behaviour (which mainly occurred at social occasions) and apathy at which it was striking that at home he could sit on the chair for hours. During neuropsychiatric examination a lack of insight seemed prominent. FBI (26) and SRI (36) were relatively high and the neuropsychological examination did not show a typical bvFTD profile with only a memory impairment. There was a discrepancy between the neurologist and radiologist regarding interpretation of the MRI brain results: the neurologist concluded that the MRI brain was appropriate for normal aging while the radiologist assessed the MRI results as supportive for bvFTD. Due to a no show, the patient had only one MRI during 2 years of follow up. Five years after the baseline visit, the diagnosis bvFTD was rejected due to a lack of decline at neuropsychological testing, clear relational problems, lack of progression of frontotemporal atrophy on brain MRI at that time and the absence of supportive results at FDG PET. All symptoms could be explained by severe relational problems between the patient, with avoidant character traits, and his wife. If there would have been more insistence on repeating MRI of the brain after two years, the misdiagnosis could probably be corrected at T2.

One patient changed diagnosis from possible bvFTD (T2) to a psychiatric disorder (T$_{final}$).
B. While at baseline patient B was already diagnosed with a major depression with psychotic features, after two years of follow up the behavioral problems (mainly apathy) turned out to be progressive which led to a diagnosis of possible bvFTD. Genetic screening was negative. Neuropsychological tests and repeated imaging of the brain (both MRI and FDG PET) remained normal during follow up and after five years there appeared to be insufficient evidence for impending dementia and the behavioral problems were classified as being part of a depression. Psychiatric treatment including pharmacotherapy and electroconvulsive therapy had some effect on the depressive symptoms but the depression did not go into complete remission.

Two patients changed diagnosis from a psychiatric disorder or relationship problems (T2) into probable bvFTD (T$_{final}$).
C. Patient C was a 64 year old male when he consulted a neurologist for the first time. He had serious mood problems in combination with disinhibition which raised a hypothesis of dementia, specifically bvFTD, by his general practitioner. At the neurologist, a diagnosis of bvFTD was not made because of a depressive mood in combination with low scores at informant based questionnaires for behavioral changes (SRI and FBI), a neuropsychological profile with only memory problems and imaging without abnormalities (both MRI and FDG PET). The patient was evaluated by a psychiatrist who concluded a major depressive disorder. At two years of follow up, after psychiatric treatment, the depression was in remission. A repeated MRI of the brain showed little progression of frontal atrophy. Because disinhibition was the only remaining behavioral problem the patient did not fulfil criteria for bvFTD and a diagnose of probable bvFTD was not made. After five years however the behavioral problems, as well as the neuropsychological tests and MRI, showed a clear progression which resulted in a diagnosis of probable bvFTD. In retrospect, the progression of the clinical profile and MRI results were already apparent after two years of follow up. Although the patient did not fulfil all bvFTD criteria it could have been possible to conclude the very strong hypothesis of probable bvFTD within this time frame. Besides, the depression was already in remission at two years of follow up so although it was difficult to conclude impending dementia with highest certainty there was no longer a psychiatric disorder either.
D. Patient D changed diagnosis from "relational problems" into probable bvFTD. After five years of follow up, he had a similar course like the case just described in the sense that subtle temporal atrophy at MRI was already present a baseline and at T2. At two years of follow up he did not fulfil enough 'behavioral criteria' for bvFTD but the behavioral problems progressed between two and five years of follow up which made a bvFTD diagnosis inevitable. The relationship problems which blurred the picture, could have been secondary to the impending dementia.

Two patients changed diagnosis from a psychiatric disorder into neurodegenerative diseases (T$_{final}$).
E. This patient changed diagnosis from bipolar disorder at T2 into AD at T$_{final}$. He had memory complaints at first presentation which were not objectified by neuropsychological tests and MRI of the brain at baseline was normal. The FDG-PET scan, which was performed already at baseline, was supportive for AD but was inadvertently disregarded for the first two years of follow up as the clinical impression was fitting a mood disorder. He was diagnosed with bipolar disorder for more than ten years which strengthened the hypothesis of a psychiatric disorder. While he was newly diagnosed with AD after more than two years of follow up, in retrospective his cognitive impairment progressed within the first two years.
F. Patient F changed diagnosis from an unclear psychiatric presentation, finally labelled as an agitated depression at T2 (described figure 3), into the diagnosis vascular dementia after five years of follow up. The lacunar infarcts at MRI of the brain were already present at baseline but were not seen as a cause for the clinical picture. The final diagnosis was only made after more than three years of follow op due to deterioration of cognitive test results fitting a vascular dementia profile.

Two patients changed diagnosis from possible bvFTD into other neurodegenerative diseases.
G. Patient G changed diagnosis from possible bvFTD at T2 into vascular dementia after five years of follow up and in retrospect it was clear that cerebrovascular damage was already present at MRI of the brain at baseline but because of the clinical profile, executive dysfunction at neuropsychological examination and a very low score at Ekman faces test (<20) possible bvFTD was initially considered more likely as diagnosis. However, MRI and FDG-PET of the brain were not supportive of a bvFTD diagnosis and genetic screening was negative. During follow up there was no apparent progression of behavioral problems and MRI did not show frontal or temporal atrophy.
H. Patient H had a diagnosis of possible bvFTD at baseline and because of the absence of a conclusive diagnosis at T2 this diagnosis of possible bvFTD persisted. After two years of follow up there was a strong suspicion of having impending dementia that could not be classified. The patient deceased within 5 years of follow up and in retrospect a diagnosis of PSP was considered most likely

Clinical Hallmarks of Patients That Switched Diagnosis

Between T0 and T2, a total of 29 (21.2%) patients switched diagnosis, and 8 cases (5.8%) switched diagnosis after T2. It's clinically relevant to describe the clinical hallmarks from cases that switched diagnosis to identify clinical characteristics of patient that are at risk of misdiagnosis. We therefore carefully examined the clinical records of these patients (Figs. 3 and 4). We identified three main clinical hallmarks or pitfalls that contributed to diagnostic instability, including;

i) No MRI of the brain was repeated after 2 years when the first MRI was not conclusive or nonsupporting for bvFTD;

ii) A patient meeting clinical Rascovsky criteria only on informant-based history whilst meeting a probable bvFTD diagnosis based on an abnormal FDG-PET scan alone in the presence of a normal MRI;

iii) A diagnosis of possible bvFTD without disease progression at 2 years of follow-up was endured.

DISCUSSION

This study aimed to investigate diagnostic (in)stability over time of the LOF study and which clinical characteristics contribute to this (in)stability. This investigation can guide clinicians that are in diagnostic doubt when assessing patients with late onset behavioral changes suspect for bvFTD, PPD or OND, when to say it is FTD. Between baseline and the 2 year follow-up visit, 29 (21.2%) patients switched diagnosis. After the 2 years, fewer patients switched diagnosis (5.8%).

Multiple clinical lessons can be learned from carefully examining the cases that switched diagnosis. First, a possible bvFTD diagnosis without clinical progression after 2 years is most likely to switch diagnosis. If genetic testing is negative and the MRI scan is clear of atrophy or vascular lesions, a possible bvFTD diagnosis is probably a reference to the phenocopy syndrome of bvFTD[27,28] or an underlying psychiatric disorder. This warrants clinicians to consider a possible bvFTD diagnosis only as differential diagnosis and to monitor the patient closely before making a false, life changing diagnosis that can withhold adequate psychiatric treatment. Second, we found that an informant-based history can point strongly to meet all clinical bvFTD criteria but that in case of inconclusive neuroimaging results it is necessary to ask an additional informant (preferably from outside the family) for information about symptom progression over time. Third, when a patient has late-onset behavioral changes with frontal or temporal brain atrophy on the MRI within 2 years of follow up but the patient does not fulfil enough bvFTD criteria: it is very likely that the patient will develop probable bvFTD over time. Likewise, if a patient fulfils the bvFTD criteria but imaging only shows subtle frontal or temporal atrophy, a repeated MRI after 2 years gives clearance: if there is (mild) progression of subtle atrophy it seems very likely that probable bvFTD is the case. These clinical lessons that could be concluded from this study, are in line with the clinical recommendations to distinguish bvFTD from psychiatric disorders by the NIC-FTD consortium. Among those are the recommendations to include social cognition tests in the neuropsychological testing for bvFTD, the implementation of a standardized review protocol of a brain MRI with validated visual atrophy rating scales and to mainly use a FDG-PET for excluding bvFTD.[16,29] In retrospect, if these clinical recommendations were available at the time and taken into account at baseline, together with our clinical lessons, the diagnostic switches after 2 year of follow-up could have been prevented. Noteworthy, in our study, the Ekman Faces test was included as social cognition test in neuropsychological examination at baseline, which on a group level, showed that the bvFTD group has a lower score on the Ekman Faces test compared to the PPD group and to the OND group. Likewise, previous work from our group has shown that the Ekman-60 can be successful in differentiating between bvFTD and other neurodegenerative disorders and psychiatric diseases.[22] Yet, all twelve patients that switched from bvFTD to PPD between T0 and T2 scored below the cut-off of 46/60 points on the Ekman Faces test. This supports the importance to include social cognitive tasks in the diagnosis of bvFTD but also emphasizes the need of a specific social cognition test or combination of tests that can accurately distinguish bvFTD from PPD and OND.[30] Of importance, the NIC-FTD consortium recommended in 2020 to use Neurofilament light (NfL) serum or CSF levels to help distinguish between PPD

and neurodegenerative disorders such as FTD. Unfortunately, there were no NfL levels clinically available at the time of the LOF-study and these could not be taken into consideration by the clinicians.

The comparison of the characteristics, demographics and clinical, neuropsychological and neuro-imaging examinations measured at baseline between the endpoint (T_{final}) diagnostic groups (bvFTD, PPD and OND) were in agreement with previous analysis when the diagnostic groups, determined at T2 of the LOF study, were compared.[22,31]

As limitation, this study had significant delays due to the implemented General Data Protection Regulation in May 2018 which resulted in a change in methods to retrieve the data from the general practitioner or specialist. Furthermore, the majority of the LOF participants were not clinically assessed in the memory clinic at T_{final}. In these cases, a general consensus final diagnosis was made after retrieving available medical information from the general practitioner or specialist. In addition, our study methods withheld us from investigating the effects of different treatment or different social support systems between diagnostic groups that could have influenced the clinical picture at time of the follow-up visits. Moreover, our study took place in a tertiary memory clinic. It is conceivable that bvFTD patients were referred in a later disease stage. This is supported by the median disease duration before visiting the memory clinic of 3 years for the PPD and OND group and 3.5 for the FTD group. This can have implications for the clinical examinations (e.g., neuropsychological testing and brain imaging) and information of the disease course of LOF participants already being available at baseline. Eventually, this could have influenced the differential diagnoses and diagnostic accuracy of the clinician. Nevertheless, this empathizes that the 21.2% cases that switched diagnoses within 2 years after the baseline visit might be even higher in a nontertiary memory clinic. As final limitation, it is debatable whether the diagnosis relational problems are correctly assigned to be part of the primary psychiatric disorder group. In retrospect, it is possible that these cases would have been diagnosed with the phenocopy syndrome of bvFTD based on current available literature. Although the combination of relational problems with recent life events and cluster C personality traits seem to be possible underlying psychiatric or psychological condition, an evident psychiatric disorder as cause for this phenocopy syndrome has not yet been identified.[28]

We showed that after 2 years of follow up a FTD diagnosis remains stable enough to conclude that 2 years is sufficient to say a patient with late-life behavioral disorder has FTD on the condition that our clinical lessons are taken into consideration.

AUTHORS CONTRIBUTION

DATA STATEMENT

DISCLOSURES

References

1. Snowden J, Neary D, Mann D: Frontotemporal lobar degeneration: clinical and pathological relationships. Acta Neuropathol 2007; 114(1):31–38

2. Lashley T, Rohrer JD, Mead S, et al: Review: an update on clinical, genetic and pathological aspects of frontotemporal lobar degenerations. Neuropathol Appl Neurobiol 2015; 41(7):858–881

3. Mendez MF, McMurtray A, Chen AK, et al: Functional neuroimaging and presenting psychiatric features in frontotemporal dementia. J Neurol Neurosurg Psychiatry 2006; 77(1):4–7

4. Rascovsky K, Hodges JR, Knopman D, et al: Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011; 134(Pt 9):2456–2477

5. Mendez MF, Shapira JS, Woods RJ, et al: Psychotic symptoms in frontotemporal dementia: prevalence and review. Dement Geriatr Cogn Disord 2008; 25(3):206–211

6. Lanata SC, Miller BL: The behavioural variant frontotemporal dementia (bvFTD) syndrome in psychiatry. J Neurol Neurosurg Psychiatry 2016; 87(5):501–511

7. Fieldhouse JLP, Gossink FT, Feenstra TC, et al: Clinical phenotypes of behavioral variant frontotemporal dementia by age at onset. J Alzheimers Dis 2021; 82(1):381–390

8. Ibañez A, Manes F: Contextual social cognition and the behavioral variant of frontotemporal dementia. Neurology 2012; 78 (17):1354–1362

9. Bertoux M, Delavest M, de Souza LC, et al: Social cognition and emotional assessment differentiates frontotemporal dementia from depression. J Neurol Neurosurg Psychiatry 2012; 83 (4):411–416

10. Hornberger M, Bertoux M: Reply: strategy and suppression impairments after right lateral and orbito-frontal lesions. Brain: J Neurol 2016; 139:e11

11. Tsoukra P, Velakoulis D, Wibawa P, et al: The diagnostic challenge of young-onset dementia syndromes and primary psychiatric diseases: results from a retrospective 20-year cross-sectional Study. J Neuropsychiatry Clin Neurosci 2022; 34(1):44–52

12. Zapata-Restrepo L, Rivas J, Miranda C, et al: The psychiatric misdiagnosis of behavioral variant frontotemporal dementia in a colombian sample. Front Neurol 2021; 12:729381

13. Woolley JD, Khan BK, Murthy NK, et al: The diagnostic challenge of psychiatric symptoms in neurodegenerative disease: rates of and risk factors for prior psychiatric diagnosis in patients with early neurodegenerative disease. J Clin Psychiatry 2011; 72(2):126–133

14. van Vliet D, de Vugt ME, Bakker C, et al: Time to diagnosis in young-onset dementia as compared with late-onset dementia. Psychol Med 2013; 43(2):423–432

15. Krudop WA, Dols A, Kerssens CJ, et al: The pitfall of behavioral variant frontotemporal dementia mimics despite multidisciplinary application of the FTDC criteria. J Alzheimers Dis 2017; 60 (3):959–975

16. Ducharme S, Dols A, Laforce R, et al: Recommendations to distinguish behavioural variant frontotemporal dementia from psychiatric disorders. Brain 2020; 143(6):1632–1650

17. Krudop WA, Kerssens CJ, Dols A, et al: Identifying bvFTD within the wide spectrum of late onset frontal lobe syndrome: a clinical approach. Am J Geriatr Psychiatry 2015; 23(10):1056–1066

18. McKhann GM, Knopman DS, Chertkow H, et al: The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7(3):263–269

19. McKeith IG, Dickson DW, Lowe J, et al: Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65(12):1863–1872

20. Román GC, Tatemichi TK, Erkinjuntti T, et al: Vascular dementia: diagnostic criteria for research studies: report of the NINDS-AIREN International Workshop. Neurology 1993; 43(2):250–260

21. Krudop WA, Kerssens CJ, Dols A, et al: Building a new paradigm for the early recognition of behavioral variant frontotemporal dementia: late onset frontal lobe syndrome study. Am J Geriatr Psychiatry 2014; 22(7):735–740

22. Gossink F, Schouws S, Krudop W, et al: Social cognition differentiates behavioral variant frontotemporal dementia from other neurodegenerative diseases and psychiatric disorders. Am J Geriatr Psychiatry 2018; 26(5):569–579

23. Vijverberg EG, Wattjes MP, Dols A, et al: Diagnostic accuracy of MRI and Additional [18F]FDG-PET for behavioral variant frontotemporal dementia in patients with late onset behavioral changes. J Alzheimers Dis 2016; 53(4):1287–1297

24. Snowden JS, Rollinson S, Thompson JC, et al: Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations. Brain 2012; 135(Pt 3):693–708

25. Ducharme Simon, Bajestan Sepideh, Dickerson Bradford C, et al: Psychiatric presentations of C9orf72 mutation: what are the diagnostic implications for clinicians? J Neuropsychiatry Clin Neurosci 2017; 29(3):195–205

26. Allaire JJ, Gandrud C, Russell K, Yetman CJ: networkD3: D3 Java-Script Network Graphs from R. R package version 0.4. https://CRAN.R-project.org/package=networkD3

27. Devenney EM, Ahmed RM, Halliday G, et al: Psychiatric disorders in C9orf72 kindreds: study of 1,414 family members. Neurology 2018; 91(16):e1498–e1507

28. Gossink FT, Dols A, Kerssens CJ, et al: Psychiatric diagnoses underlying the phenocopy syndrome of behavioural variant frontotemporal dementia. J Neurol Neurosurg Psychiatry 2016; 87 (1):64–68

29. Pressman Peter S, Matlock Daniel, Ducharme Simon: Distinguishing behavioral variant frontotemporal dementia from primary psychiatric disorders: a review of recently published consensus recommendations from the Neuropsychiatric International Consortium for Frontotemporal Dementia. J Neuropsychiatry Clin Neurosci 2021; 33(2):152–156

30. Dodich A, Crespi C, Santi GC, et al: Evaluation of discriminative detection abilities of social cognition measures for the diagnosis of the behavioral variant of frontotemporal dementia: a systematic review. Neuropsychol Rev 2021; 31(2):251–266

31. Vijverberg EGB, Gossink F, Krudop W, et al: The diagnostic challenge of the late-onset frontal lobe syndrome: clinical predictors for primary psychiatric disorders versus behavioral variant frontotemporal dementia. J Clin Psychiatry 2017; 78(9):e1197–e1203